Addressing Geopolitical Challenges to the Price of Medicines
Tuesday 26th October 2021 – 4pm UK time
To mark the 10th anniversary of the launch of the Health Policy & Technology journal, the HPT team, in partnership with the Fellowship of Postgraduate Medicine, is organising an online conference webinar series on key Health Policy and Technology themes of national and international interest.
Innovative health technologies are often enthusiastically viewed as game changers however their costs are sharply criticised. Take, for example, CAR T-Cell therapy, which has a price of up to 500,000 euro per person.
This raises many questions. For example, what is a fair price for a medicine? How should the price be related to the effectiveness or the number of end-users? What about the risks taken by the company to get the therapy to market? What about the risks taken by the end-user who use the medicine? And what about the risks taken by the payer? Is it unrealistic to think that there is a solution that would be fair to all stakeholders? And how can we ensure that the whole system is financially sustainable in the long term?
Expectations and challenges in the European Union
Carin Uyl-De Groot, Erasmus School of Health Policy & Management, Rotterdam, The Netherlands
Why has R&D has moved from large impact cardiovascular indications to targeted treatments?
John LaMattina, Healthcare Contributor, Forbes
Better and affordable medicines: new approaches to democratize innovation and R&D for medicines
Yannis Natsis, Manager Universal Access, European Public Health Alliance
Role of distributed R&D: the shift from Big Pharma to Biotech
Joe Damond, Executive Vice President for International Affairs at the Biotechnology Innovation Organization (BIO)
Ken Redekop, Editor-in-Chief, Health Policy and Technology, Rotterdam, The Netherlands
Donald Singer, President, Fellowship of Postgraduate Medicine, London, UK